Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “Ono”), Bristol Myers Squibb Co. (New Jersey, USA; “BMS”), and Dana-Farber Cancer Institute, Inc. (Massachusetts, USA; “Dana-Farber”) have entered into a global agreement to settle all disputes relating to the anti-PD-1/PD-L1 antibody patents recognized as the Honjo-Freeman Patents in the United States or the Honjo Patents in Japan.

　Under the agreement, Ono and BMS will make a lump-sum payment to Dana-Farber, with the possibility of additional payments in the future. All other terms of the agreement are confidential.
　This resolution paves the way for our continued focus on pioneering discoveries that have enabled cancer immunotherapies and advances our shared goal to provide extraordinary care for our patients.

　The impact of this matter on the consolidated financial results for the current fiscal year ending March 31, 2023 will be disclosed at the announcement for the financial results for the fiscal year ending March 2023.